Camrelizumab, Apatinib, Temozolomide Combination Is Efficacious for Acral Melanoma
In all, 32 patients had a response, translating to an ORR of 66.7%.
In all, 32 patients had a response, translating to an ORR of 66.7%.
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
The higher response rates with concurrent therapy did not translate to improvements in survival.
Higher total fish intake is associated with increased risk for malignant melanoma and melanoma in situ.
Patient awareness of sun damage doesn’t always translate into safer sun practices, finds Lisa Nyanda-Manola, MD. She describes how she counsels her patients, especially those with skin of color, to protect themselves.
Researchers sought to investigate the connection between immune checkpoint inhibitors (ICIs) and immune- and autoimmune-related adverse events in older patients diagnosed with melanoma.
The outcome of second-line targeted therapy after progression on PD-1-based immunotherapy in patients with BRAFV600-mutant melanoma is examined.
Recurrence-free survival in patients with melanoma treated with pembrolizumab are reported.
Data from the Surveillance, Epidemiology, and End Results (SEER) program are used to compare melanoma incidence and mortality trends among Black and White patients from 2014 to 1975.
Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.